Superior outcomes after video-assisted thoracoscopic surgery (VATS) pulmonary lobectomy have been demonstrated, compared with thoracotomy, for patients affected by early-stage non-small cell lung cancer (NSCLC). However, in an era of rising health care costs and controlled resources, the overall medical cost of surgical procedures is measured by the hospitals' marketing offices. Several factors such as surgical technique, conversion rate, length of stay, post-operative complications occurrence and mainly the introduction of new surgical technologies (disposables and devices) could influence the cost-effectiveness of VATS procedures. However, increased operating room costs are counteracted by shorter hospital stay and reduced ward bed stays providing further resources for other patients. Thus, choosing a surgical approach and assessing whether a specific technique is cost-effective is mandatory for a modern thoracic surgeon to justify its expenses. This review tries to reach a conclusion by comparing all recent studies reporting a cost analysis for VATS lobectomy, especially for new technologies used for VATS lobectomy. Nevertheless, no sufficient evidences are published to assess VATS new technologies sustainability and further cost analyses are necessary before VATS lobectomy expense is deemed justified. 3:152 jovs.amegroups.com -*, study comparing the stapler (ST) vs. electrocautery and hemostatic sealant patch (ES) in VATS lobectomy and showing a saving of €1,432.90 using ES; **, staplers. LOS, length of stay; PLOS, prolonged length of stay; OT, open thoracotomy; VATS, video-assisted thoracic surgery.
A terrific interest has been generated by the video-assisted thoracic surgery (VATS) approach to lung lobectomy in recent years. Less morbidity and faster recovery after VATS lobectomy (VATSL) have been proved compared to conventional thoracotomy approach. However, the VATS new technologies costs have been discussed about whether this minimally invasive surgical approach for lung surgery may compromise hospital sustainability. The main issue is often expressed concerning the cost of stapling devices and increased operative time. The importance of debating this issue has been addressed not only to determining how patients are operated on, but to understanding how new technologies impact on hospital costs.
The value of health care, a concept equivalent to the outcomes achieved relative to money spent is gaining a terrific relevance in the current health care concept all over the world. As a result, health care reimbursement schemes will be undoubtedly changing over the next few years, and the current fee-for-service reimbursement scenario is being replaced by a bundled payment strategy for procedural. The value of health care increases when risk-adjusted clinicalfinancial data are understood to better design financial arrangements. Awareness of such factors makes surgeons implemented for quality improvement attitude and focused resource use.
This review helps to obtain the prospect of the experience of how VATS cost analysis evolved over the years. Systematic clinical evidence production after the increase of technological sophistication is required to precisely evaluate the VATS costs and to identify potential risk factors raising costs. Huge The overall operative procedure time (170.6 vs. 196.3 min), postoperative length of stay (LOS) (5.7 vs. 5.5 days), number of lymph nodes sampled (6.2 vs. 7.0), and time spent in the intensive care unit (2.1 vs. 2.4 days) did not vary between both groups. The average cost per procedure did not vary significantly-$14,003.61 compared with $15,588.11 for thoracotomy and VATS, respectively. They concluded that VATS group was associated with no reduction in postoperative LOS and a nonsignificant reduction in the amount of time spent in the intensive care unit. Postoperative perception of pain did not vary between either group. Pain perception did, however, correlate strongly with time from operation. Cost did not vary significantly between both groups, with VATS being equivalent to thoracotomy in terms of cost.
Droghetti et al. (2) in 2017 evaluated the direct costs of pulmonary lobectomy hospitalization, comparing two different surgical devices for the interlobar fissures division: stapler (ST) vs. electrocautery and hemostatic sealant patch (ES). Use and maintenance of technology, equipment and operating room; administrative plus general costs; and 30-day use of post-surgery hospital resources were considered for 40 patients. Hospital perspective was used to conduct the cost analysis. A patient undergoing pulmonary lobectomy costs €9,744.29/$11,559.9 on average. This data could vary from €9,027/$10,709.1 (using ES) to €10,460/$10,709.1 (using ST). In the ES group, the mean time of hospital stay (11.0 vs. 14.3 days) and costs were significantly affected by the overall lower incidence (50% vs. 95%, P=0.0001) and duration of air leakage (1.7 vs. 4.5 days, P=0.0001). The lower incidence of complications in the ES group also determined a substantial cost saving. The main key cost burden was staff employment (42%), then consumables (34%) and operating room costs (12%). There was an overall saving of around €1,432.90/$1,699.7 when using ES patch for each pulmonary lobectomy. The authors concluded that air leakage incidence and duration, as well as hospitalization rates could significantly be reduced by the ES use.
Medbery et al. (3) in 2014 showed the VATSL cost variability by analyzing 149 VATSLs for lung cancer. Median LOS was 4 days, with 30-day mortality and morbidity rates of 0.7% and 37.6%, respectively. Mean operative and postoperative costs per case were $8,492.31 (± $2,238.76) and $10,145.50 (± $7,004.71), respectively, resulting in an average overall hospital cost of $18,637.81 (± $8,244.12) per patient. Patients with chronic obstructive pulmonary disease and coronary artery disease, as well as post-operative urinary tract infections and blood transfusions, were associated with statistically significant variability in cost.
They concluded that variability in cost associated with VATSL was driven by assorted patient and clinical variables.
Farjah et al. (4) in 2014 analyzed the complications after VATS pulmonary resection leading to increased costs of care. The authors analyzed 90-day costs comparing VATSL vs. open lobectomy (OL) and investigating if differential health care use after discharge might cause any observed differences in costs. A cohort study (2007-2011) of patients with lung cancer who had undergone resection was performed using Market Scan, a nationally representative sample of persons with employer-provided health insurance. Total costs reflected payments made for inpatient, outpatient, and pharmacy claims up to 90 days after discharge. Out of 9,962 patients, 31% underwent VATSL. Compared with thoracotomy, VATS offered a lower rate of prolonged LOS (PLOS) (3.0% vs. 7.2%; P<0.001), 90-day emergency department (ED) admission (22% vs. 24%; P=0.005), and 90-day readmission (10% vs. 12%; P=0.026). VATSL showed a lower risk-adjusted 90-day costs of $3,476 (P=0.001). Differential rates of PLOS appeared to explain this cost difference. After adjustment for PLOS, costs were $1,276 lower for VATS, but this difference was not significant (P=0.125). In the fully adjusted model, PLOS was associated with the highest cost differential (+ $50,820; P<0.001). VATSL showed a lower 90-day costs, apparently consecutive to lower rates of PLOS. Deen et al. (5) in 2014 retrospectively defined the cost of care for lobectomy and segmentectomy, comparing thoracotomy (n=69), VATS (n=58) and robotic approaches (n=57), in patients affected by early stage lung cancer, carcinoid, or metastatic foci who had anatomic resection. Ten categories were considered to calculate direct hospital cost. The authors distanced the robotic and VATS cases for capital depreciation. Key costs were varied in a sensitivity analysis. No statistically significant difference in overall cost between VATS and open cases (Δ = $1,207) or open and robotic cases (Δ = $1,975) were shown. Roboticspecific supplies made robotic cases cost $3,182 more than VATS (P<0.001). Intensive care unit, respiratory therapy and laboratories raised costs in thoracotomy cases. Thus, VATS was the least expensive surgical approach. Lessening robotic operative time, avoiding unnecessary laboratory examination and minimizing intensive care unit stays will help decrease direct hospital costs.
Swanson et al. (6) in 2014 performed a propensity score matched analysis comparing robot-assisted thoracic surgical (RATS) lobectomy with conventional VATSL and wedge resection. Using the Premier hospital database, patients undergoing lobectomy, segmental resection, or wedge resection through VATS were considered. Out of 15,502 patient reports analyzed, 96% (n=14,837) were performed without robotic assistance. Higher average hospital costs per patient was associated with the use of robotic assistance. The average cost of inpatient procedures with RATS was $25,040.70 vs. $20,476.60 for VATS (P=0.0001) for lobectomies and $19,592.40 vs. $16,600.10 (P=0.0001) for wedge resections, respectively. Inpatient operating time were longer for RATS lobectomy than VATSL (4.49 vs. 4.23 h; P=0.0959) and wedge resection (3.26 vs. 2.86 h; P=0.0003). No differences in LOS and adverse events were registered.
Swanson et al. (7) in 2012 compared VATS and OL procedures in terms of hospital costs and perioperative outcomes using The Premier Perspective Database (Premier Inc., Charlotte, NC, USA). A total of 3,961 patients undergoing pulmonary lobectomy through open (n=2,907) or VATS (n=1,054) approach. The open approach showed higher hospital costs than VATS; $21,016 vs. $20,316 (P=0.027). A significant association between surgeon experience and cost was proved adjusting for surgeon experience with VATS over the 6 months prior to each operation. Average costs ranged from $22,050 for low volume surgeons to $18,133 for high volume surgeons. Not significant cost differences by surgeon experience for open lobectomies were shown and both levels were measured at $21,000. LOS for open was 7.83 vs. 6.15 days for VATS (P=0.000). Open procedures were shorter than VATS (3.75 vs. 4.09 h, P=0.000). The risk of adverse events was significantly lower in the VATS group [odds ratio (OR), 1.22; P=0.019]. Therefore, the positive economic impact of VATSL was magnified as the surgeon's experience increased.
He et al. (8) in 2011 compared the outcomes and costs between complete VATS (c-VATS) or assisted VATS (a-VATS) major pulmonary resection in 1,058 patients affected by non-small cell lung cancer (NSCLC). Mean operative time was shorter in the a-VATS cohort vs. the c-VATS group (P=0.038). Overall survival (OS) at 5 years was 55.3% [95% confidence interval (CI), 50.6-60.0%] in the c-VATS group and 47.7% (95% CI, 41.2-54.2%) in the a-VATS group (P=0.404). Predictive factors for OS were gender, final pathology, TNM stage and pT status, according to multivariate analysis. The total cost of a-VATSL was lower than that of c-VATSL, but no differences were shown in postoperative results. a-VATS could be a particularly attractive option in developing countries due to its less expensive costs.
Cho et al. (9) investigated on the costs of VATSL vs. OL, analyzing the impact of surgeon's experience level on VATSL cost.
Eight-six patients in a VATSL group and 97 patients in an OL group underwent surgery for lung cancer. Cost comparisons were performed for the VATSL (n=86) and OL (n=97) groups facing patients who had no complications and patients who showed complications considering the tumor location and the learning period of the surgeon. Postoperative complications occurred in 30.6% of patients (14 VATSL vs. 42 OL patients; P=0.05). Chest tube duration (5.4 vs. 9.1 days; P=0.000) and length of hospital stay (7.1 vs. 12.0 days; P=0.000) were shorter in VATSL group. No differences for the mean operative time was shown between VATSL and OL (145.8 vs. 136.4 min; P=0.782). The total hospital cost was lower for VATSL than for OL both among all patients ($5,391 vs. $5,593, respectively) and non-complicated patients ($4,684 vs. $4,769, respectively). Moreover, the right lower lobe, left upper lobe and left lower lobe were less expensive than all the other lobes in terms of hospital cost when lobectomy was performed through VATS. No significantly differences in costs were shown between the two groups according to surgeons' learning periods, except for the cost of anesthesia.
Gopaldas et al. (10) in 2010 used a national database to compare open vs. VATSL results. They considered 13,619 discharge records of patients who underwent pulmonary lobectomy through thoracotomy (n=12,860) or VATS (n=759). Mortality rates (3.1% vs. 3.4%; P=0.67), LOS (9.3±0.1 vs. 9.2±0.4 days; P=0.84), hospitalization costs ($23,862±206 vs. $25,125±1,093; P=0.16), wound infection rates (0.8% vs. 1.3%; P=0.15), pulmonary complications (32.2% vs. 31.2%; P=0.55) and cardiovascular complications (3.4% vs. 3.9%; P=0.43) were similar between the two groups, with no significant differences. Nevertheless, the VATS group was significantly impacted by the higher incidence of intraoperative complications than the thoracotomy group at multivariate analysis (OR, 1.6; 95% CI, 1.0-2.4; P=0.04). Moreover, a higher number of patients with annual income greater than $59,000 underwent VATSL than patients with income less than $59,000 (35.7% vs. 25.4%; P<0.0001). Thus, intraoperative complications were more frequent (1.6 times) in patients who underwent VATSL than patients who underwent OL. However, short-term mortality, LOS, and hospitalization costs were similar between the two groups of patients. There seemed to be a socioeconomic disparity between VATS and open thoracotomy patients.
Casali et al. (11) in 2009 investigated the overall economic sustainability of a VATS program comparing the costs of VATS and OL. Direct medical costs [disposables, theatre time, high dependency (HDU) unit stay, hospital stay] were assessed and stratified by lobectomy type. Mean theatre cost for a VATSL was $2,533±230 vs. $1,280±54 for a thoracotomy lobectomy (P=0.00001). Mean HDU cost was respectively $1,713±236 and $2,571±80 for a VATS and a thoracotomy lobectomy (P=0.00001). Mean cost of hospital stay for a VATSL was $3,776±281 vs. $4,325±154 for an open one (P=0.00001). The overall cost was less for a VATSL ($8,023±565) than the cost for an OL ($8,178±167, P=0.0002). VATS bilobectomy was slightly more expensive than an open one: $8,702±350 vs. $8,655±466 with no significant difference ($47, P=ns). Shorter hospital stay neutralized increased theatre costs (disposables and time). Importantly, the reduced HDU and ward bed stays allow free resources for new cases.
McKenna et al. (12) in 2007 aimed to show if a fasttracking protocol after VATSL provided a minimal LOS without raising morbidity and mortality or causing a readmission to the hospital. VATSLs were performed without routine postoperative laboratory examination or chest X-Rays. The chest tubes were removed when the quantity of fluid drained was less than 300 mL in a 24 h period and there was no air leak present. The patient was discharged home with a Heimlich valve if air leak was present. All procedures were performed by a single surgeon. Mean LOS was 3.26 days. Seven of 282 patients (2.5%) were discharged with a Heimlich valve. Only one patient died. No complications were registered in 251 patients (89%). Two patients were readmitted to the hospital. No chest tubes were reinserted. The hospital LOS impacted the hospital's gross margin for a patient with Medicare coverage. The main impact for the gross margin per room in a year was the reduction of the hospital LOS from 7 to 2 days. The Medicare diagnosis-related group (DRG) 075 paid approximately $24,000 for a lobectomy, independently the LOS was 2 or 7 days. The hospital cost for the stay increased slightly with each additional day in the hospital. Thus, the gross margin was slightly reduced for each less day in the hospital. Over the course of an entire year, a large difference in gross margin was registered. A LOS of 2 days was translated in 3.5 lobectomy patients who could use that hospital room instead of one patient if the LOS was 7 days. A huge difference in the gross margin for that hospital room and a substantial savings in the financial bottom line for hospitals was sustained by the shorter LOS.
Nakajima et al. (13) in 2000 analyzed the VATSL costs in Japan, where the health care reimbursement is completely different from European or American countries. In this series, videothoracoscopic lobectomy or partial resection of the lung instead of an open thoracotomy was preferred for patients with more comorbidities or a not good performance status affected by lung carcinoma. Out of 102 patients considered for the analysis, 79 patients had primary lung carcinoma, and 23 had metastatic lung carcinoma. Sixtysix open thoracotomies and 36 thoracoscopic surgeries were performed. The mean hospital cost for the total of patients was $11,348. The total charges accrued in the operating room amounted to 63% of the hospital costs. LOS was significantly shorter in the VATS group (17.3 days) compared with the thoracotomy group (23.8 days). Laboratory examinations, anesthesia, disposable equipment, and hospitalization costs were significantly higher in patients who underwent open thoracotomy compared with the patients who underwent videothoracoscopy. No statistically significant differences in the costs for medication or surgical fees between the two groups were shown. They were lower than the charges for patients undergoing open thoracotomy at the authors' hospital. The lower hospital charges for patients undergoing videothoracoscopic surgery were attributable mainly to the less invasive nature of VATS procedures, lessening the risk of postoperative complications in relatively poor health patients.
In conclusion, to date, when a VATS approach is used, significant cost savings seem to be reported compared to a thoracotomy for lung cancer surgery (14, 15) . If concern about the cost of VATS equipment is raised, the VATS approach is clearly favored over a thoracotomy (16, 17, 18) offering a significant hospital savings associated with better outcomes, particularly when an experienced surgeon performs the surgery. Moreover, in the era of cost containment, a fast-tracking protocol is suggested to lessen cost and shorten the LOS after a lobectomy. However, no standardized items were followed to perform a cost analysis, thus all reports present in literature are extremely different, evaluating not similar and not comparable aspects of VATSL expense. Furthermore, no specific numbers are reported for new instruments or technological devices applied for VATSL, making really challenging the cost analysis in the new era of minimally invasive surgery. Prospective studies considering standardized variables and economic measurement tools are necessary to better understand the real burden of new technologies for VATSL.
